Injectable PrEP: Understanding Trial Results and the 69% Figure

Long-acting injectable cabotegravir is a highly effective PrEP option for people who prefer not to take daily tablets. The “69%” from HPTN 083 is a relative reduction in HIV incidence compared with daily TDF/FTC in that trial, not an absolute efficacy of only 69%.

Thinking about PrEP? Talk with a provider near you * Prices and free services vary by provider. Please check the details before booking. Find a provider → 02

Trial Evidence

HPTN 083 enrolled cisgender men and transgender women who have sex with men; HPTN 084 enrolled cisgender women. Both found cabotegravir superior to oral comparison PrEP. The difference reflects both pharmacology and incomplete adherence to daily tablets during the trials.

Use and Monitoring

HIV-negative status must be confirmed before starting and before every injection. Injections follow the product schedule, with a plan for late or discontinued dosing. Drug levels persist during a long tail, and HIV acquired then can select resistance. Injection-site reactions are common.

Find a PrEP service that fits your needs * Prices and free services vary by provider. Please check the details before booking. View PrEP services → 03

Choosing a PrEP Option

Injectable PrEP suits some people; oral PrEP suits others. Choice depends on clinic access, convenience, kidney and hepatitis B status, cost, and preference. Both prevent HIV, not other STIs.

Verified references

Links and relevance to the article’s main topic were reviewed on 13 August 2026. Each source supports only the scope stated in the original document and does not replace personalised medical, legal, or service advice.

1. US FDA: Apretude prescribing information Accessed 13 August 2026
2. CDC: Clinical Guidance for PrEP Accessed 13 August 2026
3. WHO: HIV and AIDS fact sheet Accessed 13 August 2026